Alpha¹ by KaimenConfidential

Kaimen Rigor review

Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial.

Sanmarti R, Pérez-García C, de-Toro FJ, Salvador G, Escudero-Contreras A, Cuervo A, Graell E, Reina D, Kanterewicz E, Corominas H, Urionaguena-Onaindia I, López-Lasanta M, Olivé A, Sala-Gómez M, Frade-Sosa B, Morlà-Novell RM, Polino L, Meraz-Ostiz JA, Oreiro N, Blanco FJ, Pérez-Nadales I, Ortega-Castro R, Busquets-Pérez N, Gómez-Centeno AD, Camacho O, Rodríguez-Cros JR, Millan-Arciniegas AM, García-Llorente JF, Borrell H, Prior-Español Á, Castell-Quiñones S, Cruceta A, Bonfill E, Domenech-Gómez G, Roca-Fàbregas A, Ríos J, Tobalina-Maestre L, Gómara MJ, Haro I

DOI: 10.1038/s41591-026-04395-6
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-20

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/6ee8c655-5d89-406f-80fa-2c965d75b8ca is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

StatisticsImpossible or misreported statistic ×3−3★
IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ReportingStudy design partially met−0.25★
ReportingData & code availability partially met−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 4 reported means were read, and their group size is not stated where the values are printed. These checks need the count the mean was averaged over, so none was performed.

Biggest issues3 demonstrable

01Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
22.9% does not match the reported count 8/36
“8 (22.9%) of the 36 participants”
Find in source
02Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
22.9% does not match the reported count 8/36
“8 (22.9%) of the 36 participants treated with hydroxychloroquine”
ResultsFind in source
03Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
1.8% does not match the reported count 4/34
“4/4 (1.8%)”
Table 2
04Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
Abatacept could be considered in clinical practice for patients with seropositive PR after careful discussion of risks and benefits.
“Despite the limitations of our study, abatacept could be considered in clinical practice when patients with seropositive PR are managed, after a careful discussion of risks and benefits, and individual values and preferences are incorporated into our…”
DiscussionFind in source

Findings by category

201ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 204DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted randomized open-label trial with a clear scientific premise, rigorous randomization, and adequate reporting of ethics, biological variables, and key resources. The main weaknesses are the open-label design, vague data availability, and minor statistical reporting gaps.

Both reviewers classified the study as interventional; no divergence. The evaluation covered all eight dimensions; several sub-criteria were not applicable for a human clinical trial (e.g., housing conditions, cell line authentication). The statistics verification component checked only a subset of tests; the 3 inconsistent recomputations were not flagged as decision errors and may reflect rounding.

Numerical inconsistencies

2 findings · worst critical

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks. 3 reported summary statistics mathematically impossible for the stated N (PERCENT).

Numeric forensics— values impossible for the reported sample size

PERCENT
22.9% does not match the reported count 8/36
“8 (22.9%) of the 36 participants”
Find in source
PERCENT
22.9% does not match the reported count 8/36
“8 (22.9%) of the 36 participants treated with hydroxychloroquine”
ResultsFind in source
PERCENT
1.8% does not match the reported count 4/34
“4/4 (1.8%)”
Table 2

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p = .010 · recomputed p = .010Reviewers 1, 2
Primary outcome: chi-square test for RA development at 24 months (failure imputation) in mFAS.
“7 (20.6%) of the 34 participants treated with abatacept and 18 (50.0%) of the 36 participants treated with hydroxychloroquine developed RA during the 24 months of follow-up ( P = 0.010)”
Find in source
Taken as given: The numbers 7 and 18 are the event counts in the abatacept and hydroxychloroquine groups, respectively.; The denominators are 34 and 36, so non-events are 27 and 18.; The test is a two-sided chi-square test without continuity correction.
Method: Pearson chi-square test from 2x2 contingency table using pChi2x2.
How we recomputed it: pChi2x2(7,27,18,18)
CONSISTENTreported p = .007 · recomputed p = .007Reviewer 1
Primary outcome at 12 months: chi-square test for RA development (failure imputation) in mFAS.
“During the first 12 months, using failure imputation in the mFAS population, 3 (8.8%) of the 34 participants treated with abatacept and 13 (36.1%) of the 36 participants treated with hydroxychloroquine developed RA ( P = 0.007)”
Find in source
Taken as given: The numbers 3 and 13 are the event counts in the abatacept and hydroxychloroquine groups, respectively.; The denominators are 34 and 36, so non-events are 31 and 23.; The test is a two-sided chi-square test.
Method: Pearson chi-square test from 2x2 contingency table using pChi2x2.
How we recomputed it: pChi2x2(3,31,13,23)
CONSISTENTreported p = .030 · recomputed p = .030Reviewers 1, 2
Time-to-event analysis: log-rank test for RA-free survival.
“participants treated with abatacept had a significantly longer time to progression to RA (hazard ratio 0.27, 95% confidence interval 0.07 to 0.96; log-rank test P = 0.0299)”
Find in source
Taken as given: The log-rank test statistic is approximately 4.71 (derived from the p-value and 1 degree of freedom).; The test is two-sided.
Method: Chi-square test with 1 degree of freedom from log-rank statistic.
How we recomputed it: pChi2(4.71,1)
CONSISTENTreported p = .019 · recomputed p = .019Reviewer 2
Primary outcome comparison (available data only) using chi-square test
“Using the available-data-only approach, the corresponding figures were 3 (10.0%) of 30 individuals and 10 (35.7%) of 28 individuals, respectively ( P = 0.019).”
Find in source
Taken as given: The numbers 3 and 10 are the event counts in the abatacept and hydroxychloroquine groups, respectively.; The denominators are 30 and 28, respectively.; The test used is a two-sided chi-square test without continuity correction.
Method: Pearson chi-square test on 2x2 table (3,27,10,18) using pChi2x2.
How we recomputed it: pChi2x2(3, 27, 10, 18)

lowinternal contradiction
In Table 2, the percentage for 'Eye disorders' in the abatacept column is given as 1.8% but should be 11.8% (4/34 ≈ 11.8%). This appears to be a typographical error.
“Eye disorders | 3/2 (5.6%) | 4/4 (1.8%) | 0.422”
Table 2Find in source
lowinternal contradiction
Table 1 reports female percentages as 69.5% for hydroxychloroquine and 73.5% for abatacept, but 25/36 = 69.4% and 25/34 = 73.5%, so the first is slightly off.
“Female | 25 (69.5%) | 25 (73.5%)”
Table 1Find in source

Overstated conclusions

2 findings · worst medium

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 2 only partially supported (evidence backs part of the claim; gaps or caveats remain).

overstatedReviewer 1
Abatacept could be considered in clinical practice for patients with seropositive PR after careful discussion of risks and benefits.
The study provides evidence of efficacy, but the open-label design, small sample size, and lack of long-term follow-up limit the strength of the recommendation. The authors acknowledge these limitations, but the conclusion goes beyond what the evidence can support for routine clinical practice.
Evidence: The study shows a significant reduction in RA progression, but the limitations (open-label, small sample, no imaging, no patient-reported outcomes) are discussed.
“Despite the limitations of our study, abatacept could be considered in clinical practice when patients with seropositive PR are managed, after a careful discussion of risks and benefits, and individual values and preferences are incorporated into our recommendation.”
DiscussionFind in source
partialReviewers 1, 2
No relevant differences in the evolution of autoantibody titers were observed between the two treatment arms.
Most comparisons showed no significant differences, but some individual timepoints (e.g., chimeric fibrin/filaggrin homocitrullinated peptide-IgG at month 24, CEP 1-IgA at month 3) showed statistically significant differences. The claim is broadly accurate but slightly overstated.
Evidence: Supplementary Table 12: Most comparisons non-significant, but a few significant differences noted.
“No relevant differences in the evolution of antimodified peptide and/or protein antibody titers were observed between the two treatment arms.”
AbstractFind in source
partialReviewer 2
Abatacept improved symptoms compared with hydroxychloroquine.
Abatacept reduced attack intensity and increased remission, but no difference in attack frequency.
Evidence: Remission: 19/34 vs 8/36, P=0.007; intensity reduced; frequency not significantly different.
“Abatacept was also associated with a reduced intensity of joint attacks and a higher frequency of symptom remission; however, there were no differences in the frequency of attacks between the two study drugs.”
AbstractFind in source
supportedReviewer 1
Abatacept reduced the risk of progression to RA compared with hydroxychloroquine in patients with seropositive palindromic rheumatism.
The primary outcome (RA development at 24 months) shows a statistically significant difference (P=0.010) with a risk difference of 29.4% (95% CI 8.2 to 50.7). Sensitivity analyses (ADO, per-protocol, logistic regression adjusting for imbalances) are consistent.
Evidence: Primary analysis with failure imputation: 7/34 (20.6%) vs 18/36 (50.0%), P=0.010, risk difference 29.4% (95% CI 8.2 to 50.7).
“In the primary analysis, in the modified full analysis set with failure imputation, 7 (20.6%) of the 34 participants treated with abatacept and 18 (50.0%) of the 36 participants treated with hydroxychloroquine developed RA during the 24 months of follow-up ( P = 0.010; risk difference 29.4%, 95% confidence interval 8.2 to 50.7), meeting the primary endpoint.”
AbstractFind in source
supportedReviewer 1
Abatacept was associated with a reduced intensity of joint attacks and a higher frequency of symptom remission.
The paper reports statistically significant differences in attack intensity (Mann-Whitney U-test) and remission proportion (chi-square test). However, the frequency of attacks did not differ significantly.
Evidence: Remission: 19/34 (55.9%) vs 8/36 (22.9%), P=0.007. Intensity: median 4.0 vs 7.0, P value not explicitly given but stated as statistically significant.
the proportion of patients in remission in the mFAS population was 19 (55.9%) of the 34 participants treated with abatacept, and 8 (22.9%) of the 36 participants treated with hydroxychloroquine ( P = 0.007)... The differences in the intensity of attacks during the 24-month period between the two study groups were statistically significant.
Resultsreviewer’s wording
supportedReviewers 1, 2
Both drugs were well tolerated.
Adverse event rates are reported and compared; no significant differences in serious adverse events or discontinuations. One serious adverse event in abatacept group (melena) was not considered related.
Evidence: Table 2: Any adverse events 73.5% vs 63.9% (P=0.446); serious adverse events 2.9% vs 5.6% (P=1.000).
Overall, 25 (73.5%) of the 34 participants treated with abatacept and 23 (63.9%) of the 36 participants treated with hydroxychloroquine experienced at least one adverse event... One participant treated with abatacept experienced a serious adverse event... not considered related to the study drug.
Resultsreviewer’s wording
supportedReviewer 2
Abatacept reduced the risk of progression to RA compared with hydroxychloroquine.
The primary endpoint was met with a statistically significant difference and supportive sensitivity analyses.
Evidence: Primary analysis: 7/34 vs 18/36, P=0.010; ADO: 3/30 vs 10/28, P=0.019; time-to-event HR 0.27 (95% CI 0.07-0.96).
“abatacept given for 2 years reduced the risk of progression to RA and improved symptoms.”
AbstractFind in source

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

ADEQUATESurrogate endpoint
The primary endpoint is the development of persistent arthritis fulfilling the 2010 RA classification criteria, which is a clinical outcome (development of a disease), not a surrogate biomarker. The trial directly measures progression to RA, a clinically meaningful endpoint.
“The primary outcome was the development of persistent arthritis (that is, lasting more than 1 week in the same joint) that fulfilled the 2010 RA classification criteria of the American College of Rheumatology/European League Against Rheumatism as evaluated by the participant clinicians during the 24 months of follow-up.”
Find in source
ADEQUATEEffect size
The primary effect size is a risk difference of 29.4% (95% CI 8.2 to 50.7) in the proportion developing RA, with a hazard ratio of 0.27 (95% CI 0.07 to 0.96). The authors explicitly anchor this as clinically relevant, citing that a risk difference greater than 20% is clinically relevant in similar trials.
“Overall, the risk difference between abatacept and placebo was greater than 20% in these trials, which is a clinically relevant effect size consistent with our results in individuals with PR.”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

2 findings · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions6 pass · 2 warn

Prior work is cited extensively, including observational studies on PR progression to RA, placebo-controlled trials of abatacept and rituximab in at-risk populations, and the rationale for using hydroxychloroquine as a comparator. The premise that PR is a preclinical RA state and that T cell activation is a key target is logically linked to the study objectives. Limitations of prior research (e.g., lack of RCTs in PR, small sample sizes, short follow-up) are acknowledged and addressed by the study design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise by citing prior work on palindromic rheumatism as a precursor to RA, the role of autoantibodies, and previous prevention trials with biologic DMARDs.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“A high proportion of individuals with PR develop RA (30–60% in most series)... Three placebo-controlled trials have shown the efficacy of biologic disease-modifying anti-rheumatic drugs (DMARDs) in delaying the onset of RA with the anti-B cell rituximab or preventing its onset with the T cell down-modulator abatacept.”

paraphrase[Introduction, paragraph 4]

“The key role of T cell activation in the preclinical and early phases of RA and the efficacy and safety of its inhibition with abatacept... position abatacept as a suitable alternative for a prevention trial in individuals with PR at risk of RA.”

“As we know of no other randomized clinical trials in patients with PR, we cannot compare our results with those of other trials of individuals with PR.”

Discussion ¶1Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the trial.

Evidence

“Three placebo-controlled trials have shown the efficacy of biologic disease-modifying anti-rheumatic drugs (DMARDs) in delaying the onset of RA with the anti-B cell rituximab or preventing its onset with the T cell down-modulator abatacept”

Introduction ¶2Find in source

paraphrase[Introduction, paragraph 3]

“The key role of T cell activation in the preclinical and early phases of RA and the efficacy and safety of its inhibition with abatacept in both early and established RA... position abatacept as a suitable alternative for a prevention trial in individuals with PR at risk of RA.”

absence[Introduction]

Limitations of prior research are not explicitly discussed as a separate subsection.

Randomization method (central, SAS PROC PLAN, block size multiple of two, stratified by center) and unit (individual patient) are adequately reported. Blinding is absent (open-label), which is a significant weakness, though the authors discuss this limitation. Power analysis is reported with assumptions (42% vs 11% progression, 80% power, alpha=0.05) and sample size (35 per group). Inclusion/exclusion criteria are clearly defined. Outlier handling is not explicitly addressed; missing data are handled via failure imputation and ADO. Controls are present (active comparator hydroxychloroquine). Independent replication is not reported. Replicate distinction (biological vs technical) is not applicable for a human RCT.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsINADEQUATE

outlier handlingNOT REPORTED

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 90% conf

The study design is generally rigorous with randomization, power analysis, and pre-specified inclusion/exclusion criteria, but the open-label design and lack of blinding are major limitations.

Evidence

“Randomization codes were assigned centrally using electronic Case Report Forms at the time of patient inclusion. These randomized codes were produced by PROC PLAN of the SAS, with a 1:1 ratio of assignment between both arms, in blocks multiple of two elements and stratified by center.”

MethodsFind in source

“The participants, clinicians and outcome assessors were not blinded to the treatment assignment.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“Assuming a 2-year progression rate of at least 42% in the control group and 11% in the experimental group, a sample size of 35 patients per group (total 70) was necessary to reach a power of 80% at a nominal two-sided alpha level of 0.05.”

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, sample size calculation, and pre-specified analysis populations, though open-label and lacking central adjudication.

Evidence

MethodsFind in source

Statistical analysisFind in source

“The lack of blinding is the main limitation of our study.”

Discussion ¶1Find in source

Sex is reported (Table 1: 69.5% female in hydroxychloroquine, 73.5% female in abatacept). Age is reported (median 50.5 and 53.5 years). Demographics include ethnicity (White, Hispanic, Other), smoking status, BMI, symptom duration, and serology (ACPA, RF). Species/strain/source and housing conditions are not applicable for a human trial. Sex justification is not applicable because both sexes are enrolled.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Biological variables are adequately reported for a human clinical trial, including sex, age, ethnicity, and other baseline characteristics.

Evidence

paraphrase[Results, Table 1]

“Sex: Male 11 (30.6%) | 9 (26.5%); Female 25 (69.5%) | 25 (73.5%); Age, years; median (P25, P75): 50.5 (41.5, 57) | 53.5 (45, 61)”

paraphrase[Results, Table 1]

“Ethnicity: White 32 (88.9%) | 27 (79.4%); Hispanic 3 (8.3%) | 7 (20.6%); Other 1 (2.8%) | 0 (0%)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, ethnicity, and disease-related variables.

Evidence

“Male | 11 (30.6%) | 9 (26.5%) | | Female | 25 (69.5%) | 25 (73.5%)”

Table 1Find in source

“Age, years; median (P25, P75) | 50.5 (41.5, 57) | 53.5 (45, 61)”

Table 1Find in source

The ethics committee of Hospital Clínic Barcelona is named with a reference number (HCB/2018/0768). The Spanish Agency of Medicines is also named. Written informed consent was obtained from all participants. Compliance with the Declaration of Helsinki and Good Clinical Practices is stated. The trial is registered at ClinicalTrials.gov and EudraCT.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are adequately reported, including a named ethics committee, informed consent, and regulatory compliance.

Evidence

“The protocol was approved by the ethics committee of the Hospital Clínic Barcelona (Barcelona, Spain; Reference HCB/2018/0768) and the Spanish Agency of Medicines (Reference 2018 MUH/CLIN/EC).”

Methods ¶1Find in source

“All participants provided written informed consent before inclusion in the study.”

Methods ¶1Find in source

“This study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practices.”

Methods ¶1Find in source

PASSReviewer 2· 95% conf

Ethical approval and informed consent are clearly documented.

Evidence

“The protocol was approved by the ethics committee of the Hospital Clínic Barcelona (Barcelona, Spain; Reference HCB/2018/0768) and the Spanish Agency of Medicines (Reference 2018 MUH/CLIN/EC).”

Methods ¶1Find in source

“All participants provided written informed consent before inclusion in the study.”

Methods ¶1Find in source

“This study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practices.”

Methods ¶1Find in source

The investigational products are clearly identified: abatacept (125 mg subcutaneous injections, weekly then every 2 weeks) and hydroxychloroquine (5 mg/kg per day). The manufacturer of abatacept (Bristol Myers Squibb) is mentioned in the acknowledgements. Statistical software (SAS version 9.4) is identified. Antibodies, cell lines, mycoplasma testing, and organisms are not applicable for this clinical trial. Reagents for autoantibody assays are described (ELISA methods with specific antigens) but vendor/catalog numbers are not provided for all; however, this is a secondary analysis and the primary resources (drugs) are adequately reported.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Key resources are adequately identified: the investigational drugs (abatacept and hydroxychloroquine) are named with dose and regimen, and statistical software is identified.

Evidence

“abatacept ( n = 34; 125 mg subcutaneous injections weekly during the first year and every 2 weeks during the second year) compared with oral hydroxychloroquine ( n = 36; 5 mg kg − 1 per day)”

AbstractFind in source

“Statistical analysis was performed using SAS (version 9.4; SAS Institute Inc.).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational products (abatacept and hydroxychloroquine) are identified with dose and regimen; statistical software is named.

Evidence

“Participants were randomized to abatacept (125 mg subcutaneous injections weekly) or oral hydroxychloroquine (5 mg kg − 1 per day)”

MethodsFind in source

“Statistical analysis was performed using SAS (version 9.4; SAS Institute Inc.).”

Statistical analysisFind in source

Tests are named (chi-square, Fisher's exact, log-rank, Mann-Whitney U, t-test, mixed models). Effect sizes with CIs are reported for the primary outcome (risk difference 29.4%, 95% CI 8.2 to 50.7; HR 0.27, 95% CI 0.07 to 0.96). Software is identified (SAS 9.4). Data presentation includes per-group n, box plots, and Kaplan-Meier curves. Assumptions verification (normality, equal variance) is not explicitly reported, but for a clinical trial using standard methods this is acceptable. Exact p-values are reported for the primary outcome (P = 0.010) and many secondary outcomes, though some are reported as thresholds (e.g., P < 0.001). Mathematical plausibility checks are not applicable for continuous outcomes with N > 100.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical analysis is generally rigorous with named tests, effect sizes with CIs, and software identified, but assumptions verification is not explicitly reported and exact p-values are sometimes reported as thresholds.

Evidence

“7 (20.6%) of the 34 participants treated with abatacept and 18 (50.0%) of the 36 participants treated with hydroxychloroquine developed RA during the 24 months of follow-up ( P = 0.010; risk difference 29.4%, 95% confidence interval 8.2 to 50.7)”

AbstractFind in source

“participants treated with abatacept had a significantly longer time to progression to RA (hazard ratio 0.27, 95% confidence interval 0.07 to 0.96; log-rank test P = 0.0299)”

AbstractFind in source

paraphrase[Methods, Statistical analysis]

“For the primary outcome, we conducted a chi-square or Fisher’s exact test... the time to occurrence of RA was estimated using the Kaplan‒Meier method, comparisons were performed with the log-rank test, and HRs (95% CI) were derived from a Cox model.”

PASSReviewer 2· 90% conf

Statistical methods are well described, with named tests, effect sizes with CIs, and appropriate handling of missing data.

Evidence

AbstractFind in source

“the risk difference was 29.4% (95% confidence interval (CI) 8.2 to 50.7)”

ResultsFind in source

“For the primary outcome, we conducted a chi-square or Fisher’s exact test, depending on the test requirements.”

Statistical analysisFind in source

A data availability statement is present: 'The datasets generated and/or analyzed during this clinical study are not publicly available due to restrictions related to data. Anonymized datasets may be provided by the corresponding author upon reasonable request with a response expected within 4 weeks.' This is reported_but_inadequate because it lacks a concrete managed-access platform or data-access committee. Code availability is stated as not publicly available. No repository deposit or accession numbers are provided. For a clinical trial, managed access is acceptable, but the statement is vague.

Sub-criteria

code sharingNOT REPORTED

accession numbersNOT REPORTED

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 95% conf

Data availability is stated but only via a vague 'on reasonable request' mechanism without a managed-access platform, and code is not shared.

Evidence

“The datasets generated and/or analyzed during this clinical study are not publicly available due to restrictions related to data. Anonymized datasets may be provided by the corresponding author upon reasonable request with a response expected within 4 weeks.”

Data availabilityFind in source

“The code generated during this clinical study is not publicly available due to restrictions related to data.”

Data availabilityFind in source

WARNReviewer 2· 90% conf

Data availability statement is present but vague; code is not shared.

Evidence

“Anonymized datasets may be provided by the corresponding author upon reasonable request with a response expected within 4 weeks.”

Data availabilityFind in source

“The code generated during this clinical study is not publicly available due to restrictions related to data.”

Data availabilityFind in source

Trial registration numbers are provided (NCT03669367 and EudraCT). Methods are comprehensive. Limitations are explicitly discussed, including lack of blinding, small sample size, and lack of imaging. Conclusions are appropriately cautious. Funding and competing interests are declared. Reporting guideline is not explicitly mentioned, but the paper follows CONSORT-like structure.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting transparency is good: methods are detailed, trial is registered, limitations are discussed, conclusions are proportional, and funding/COI are reported.

Evidence

“ClinicalTrials.gov identifier NCT03669367 (http://clinicaltrials.gov/ct2/show/NCT03669367) and EudraCT no. 2017-004543-20.”

AbstractFind in source

paraphrase[Discussion, paragraph 6]

“The lack of blinding is the main limitation of our study... The small sample size led to imprecision in the estimates... the lack of a follow-up period without active treatment precluded the evaluation of whether the beneficial effects of abatacept persisted after treatment withdrawal.”

“This study was funded by Bristol Myers Squibb through an ‘investigator sponsored research (ISR)’ grant (IM101-680_ 2016-ORE-0082).”

AcknowledgementsFind in source

PASSReviewer 2· 95% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“ClinicalTrials.gov identifier NCT03669367 (http://clinicaltrials.gov/ct2/show/NCT03669367) and EudraCT no. 2017-004543-20.”

AbstractFind in source

“The lack of blinding is the main limitation of our study.”

Discussion ¶1Find in source

“This study was funded by Bristol Myers Squibb through an ‘investigator sponsored research (ISR)’ grant (IM101-680_ 2016-ORE-0082).”

AcknowledgementsFind in source

Registered (2 IDs: ClinicalTrials.gov, EudraCT). No reporting guideline cited.

ClinicalTrials.gov

NCT03669367

EudraCT

2017-004543-20

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 39 references by DOI: 31 verified — 8 no DOI (shown, not verified).

NO DOI
The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Palindromic rheumatism: a response to chloroquine
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Hydroxychloroquine does not prevent the future development of rheumatoid arthritis in a population with baseline high levels of antibodies to citrullinated protein antigens and absence of inflammatory arthritis: interim analysis of the StopRA trial [abstract]
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The impact on anti-citrullinated protein antibody isotypes and epitope fine specificity in patients with early RA treated with abatacept and methotrexate
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Adjustment for baseline covariates in clinical trials – Scientific guideline
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
nQuery version 9. Advisor user’s guide
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

2 data/code links checked; 2 live.

datahttp://clinicaltrials.gov/ct2/show/NCT03669367LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://clinicaltrials.gov/ct2/show/NCT03669367LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly typo, consistency, clarity.

MINORtypoTable 2, footnote
“4/4 (1.8%)”
→ Should be 4/4 (11.8%) to match the pattern of other rows.
The percentage for 'Eye disorders' in the abatacept column is given as 1.8% but should be 11.8% (4/34 ≈ 11.8%).
MINORconsistencyResults, paragraph 1
“Twenty-six (76.5%) of the 34 individuals assigned to abatacept and 18 (50%) of the 36 individuals assigned to hydroxychloroquine included in the mFAS completed the study.”
→ Ensure consistency: 26/34 = 76.5% is correct; 18/36 = 50% is correct.
No error, but the sentence structure could be clearer.
MINORclarityMethods, Procedures
“although it was not explicitly stated in the question, it was understood that ‘intensity’ essentially referred to the degree of pain and/or functional impairment experienced by the patients.”
→ This parenthetical comment is informal; consider removing or rephrasing.
The sentence interrupts the flow of the methods description.
MINORconsistencyTable 1
“11 (32,4%)”
→ Change comma to decimal point: 11 (32.4%)
Inconsistent decimal separator.
MINORtypoTable 2
“4/4 (1.8%)”
→ Likely should be 4/4 (11.8%)
Percentage appears inconsistent with count.
MINORclarityMethods, Procedures
“although it was not explicitly stated in the question, it was understood that ‘intensity’ essentially referred to the degree of pain and/or functional impairment experienced by the patients.”
→ Rephrase to clarify the definition of intensity.
Awkward phrasing.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically sound but has notable limitations: the open-label design and vague data availability statement should be weighed by readers. The minor copyedit issues and the overstated clinical recommendation warrant attention in any correction or re-analysis.

1.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 22.9% does not match the reported count 8/36
Demonstrable critical failure — blocks the verdict from passing.
2.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 1.8% does not match the reported count 4/34
Demonstrable critical failure — blocks the verdict from passing.
3.
HIGHdata code
Replace the vague 'on reasonable request' data availability statement with a concrete managed-access mechanism (e.g., a named data access committee or platform like Vivli/YODA) in the Data availability section.
A concrete access route improves transparency and reproducibility for a clinical trial.
4.
HIGHreporting
Temper the conclusion that 'abatacept could be considered in clinical practice' to reflect the open-label design, small sample size, and lack of long-term follow-up, as noted in the Discussion.
The claim audit flagged this as overstated; the evidence supports efficacy but not a routine clinical recommendation.
5.
MEDIUMcopyedit
Correct the percentage for 'Eye disorders' in Table 2 from 1.8% to 11.8% (4/34).
The current percentage is internally inconsistent with the count and could mislead readers.
6.
MEDIUMcopyedit
Fix the decimal separator inconsistency in Table 1: change '11 (32,4%)' to '11 (32.4%)'.
Inconsistent decimal separators reduce clarity and professionalism.
7.
MEDIUMstatistics
Add a statement on verification of statistical test assumptions (normality, equal variance) or justify why they were not checked, in the Statistical analysis section.
Assumption verification is a standard expectation and currently not explicitly reported.
8.
MEDIUMstatistics
Report exact p-values for all secondary outcomes instead of thresholds like P < 0.001.
Exact p-values improve transparency and allow readers to assess evidence strength.
9.
MEDIUMdata code
Consider sharing de-identified participant data in a controlled-access repository (e.g., EGA or Vivli) with a DOI, if feasible under GDPR.
Repository deposit with a DOI enhances reproducibility and is more concrete than 'on reasonable request'.
10.
MEDIUMdata code
Share the statistical analysis code (e.g., SAS scripts) in a public repository with a DOI, even if data are restricted.
Code sharing improves reproducibility and is independent of data access restrictions.
11.
MEDIUMreporting
Explicitly state adherence to a reporting guideline such as CONSORT in the Methods or Reporting Summary.
Explicit guideline adherence is a standard expectation for clinical trials and currently not stated.
12.
LOWrigor
Add a statement on how outliers were handled in the statistical analysis (e.g., whether any data points were excluded and why).
Outlier handling is not explicitly reported, which is a minor reporting gap.
13.
LOWreporting
Clarify the manufacturer/source of abatacept and hydroxychloroquine in the Methods to fully identify the investigational products.
Full identification of investigational products is good practice, though not strictly required.
14.
LOWcopyedit
Rephrase the informal parenthetical comment about 'intensity' in Methods, Procedures, to clarify the definition.
The current phrasing is awkward and interrupts the methods description.

Full text (58,263 chars)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial.

DOI

10.1038/s41591-026-04395-6

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-20